|
Market Closed -
Nasdaq
02:30:00 20/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.2642 USD | -2.87% |
|
-17.31% | -98.55% |
| 17/11 | EyePoint, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 08:40 AM | |
| 13/11 | Stifel Adjusts Price Target on EyePoint Pharmaceuticals to $5 From $6, Keeps Buy Rating | MT |
| Market Cap | 3.01Cr 2.74Cr 2.54Cr 2.29Cr 4.3Cr 280.76Cr 4.5Cr 31Cr 12Cr 151.71Cr 11Cr 11Cr 480.58Cr | P/E 2026 * |
-0.07x | P/E 2027 * | -0.16x |
|---|---|---|---|---|---|
| Enterprise Value | -11Cr -10Cr -9.27Cr -8.39Cr -16Cr -1.03TCr -16Cr -112.09Cr -44Cr -554.88Cr -41Cr -40Cr -1.76TCr | EV / Sales 2026 * |
-54.7x | EV / Sales 2027 * | -221x |
| Free-Float |
97.33% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EYPT | Delayed | |
| EYPT | Real-time | ||
| PV3B | Real-time | ||
| PV3B | Real-time | ||
| PV3B | Delayed | ||
| PV3B | Delayed | ||
| PV3B | Delayed |
Last Transcript: EyePoint, Inc.
| 1 day | -2.87% | ||
| 1 week | -17.31% | ||
| Current month | -24.17% | ||
| 1 month | -39.95% | ||
| 3 months | -95.81% | ||
| 6 months | -97.76% | ||
| Current year | -98.55% |
| 1 week | 0.26 | 0.32 | |
| 1 month | 0.26 | 0.44 | |
| Current year | 0.26 | 18.87 | |
| 1 year | 0.26 | 19.11 | |
| 3 years | 0.26 | 30.99 | |
| 5 years | 0.26 | 30.99 | |
| 10 years | 0.26 | 39.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jay Duker
CEO | Chief Executive Officer | 67 | 10/07/2023 |
George Elston
DFI | Director of Finance/CFO | 61 | 14/11/2019 |
Ramiro Ribeiro
CTO | Chief Tech/Sci/R&D Officer | 43 | 04/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jay Duker
BRD | Director/Board Member | 67 | 10/07/2023 |
| Chairman | 77 | 10/09/2018 | |
John Landis
BRD | Director/Board Member | 73 | 25/10/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/08/26 | Others | Chief Financial Officer | -1,39,906 | 0.1669% | ||
| 18/08/26 | Buy | Director | 10,600 | 0.0126% | ||
| 10/07/26 | Exercice | Chief Executive Officer | 41,393 | 0.0494% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.87% | -17.31% | -98.15% | -96.03% | 3.09Cr | ||
| -2.29% | -5.34% | +28.73% | +128.34% | 1,23200Cr | ||
| -2.04% | -5.78% | +31.91% | +78.34% | 66TCr | ||
| -0.86% | -3.71% | +21.74% | +105.02% | 51TCr | ||
| -1.04% | -1.80% | +28.69% | +68.01% | 38TCr | ||
| -3.61% | -9.62% | +39.73% | +30.53% | 34TCr | ||
| -3.22% | -5.20% | +24.48% | +51.30% | 29TCr | ||
| -2.51% | -4.49% | -2.15% | +29.67% | 28TCr | ||
| -1.14% | -6.05% | +28.16% | +65.35% | 24TCr | ||
| -1.45% | -0.85% | +30.03% | +120.72% | 21TCr | ||
| Average | -2.10% | -4.44% | +13.32% | +58.12% | 41TCr | |
| Weighted average by Cap. | -2.04% | -2.67% | +26.93% | +87.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20.09L 18.31L 16.95L 15.33L 28.76L 19Cr 30.1L 2.05Cr 81.26L 10Cr 75.39L 73.81L 32Cr | 9L 8L 8L 7L 13.14L 8.57Cr 13.75L 93.59L 37.13L 4.63Cr 34.44L 33.72L 15Cr |
| Net income | -34Cr -31Cr -28Cr -26Cr -48Cr -3.15TCr -51Cr -344.1Cr -136.5Cr -1.7TCr -126.63Cr -123.98Cr -5.4TCr | -19Cr -18Cr -16Cr -15Cr -28Cr -1.82TCr -29Cr -198.49Cr -79Cr -982.62Cr -73Cr -72Cr -3.11TCr |
| Net Debt | -14Cr -13Cr -12Cr -11Cr -20Cr -1.31TCr -21Cr -142.74Cr -57Cr -706.59Cr -53Cr -51Cr -2.24TCr | -23Cr -21Cr -20Cr -18Cr -33Cr -2.18TCr -35Cr -237.63Cr -94Cr -1.18TCr -87Cr -86Cr -3.73TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | $0.2642 | -2.87% | 34,46,903 |
| 18/26/18 | $0.2720 | -8.08% | 36,10,328 |
| 17/26/17 | $0.2959 | -3.80% | 45,76,326 |
| 16/26/16 | $0.3076 | +0.52% | 65,46,986 |
| 13/26/13 | $0.3060 | -4.23% | 30,86,415 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EYPT Stock
Select your edition
All financial news and data tailored to specific country editions
















